Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years-Reference-Cited by-同舟云学术

Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years

Published:2012-05-29 Issue:4 Volume:158 Page:528-538
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Hollak Carla E. M.¹,Belmatoug Nadia²,Cole J. Alexander³,vom Dahl Stephan⁴,Deegan Patrick B.⁵,Goldblatt Jack⁶,Rosenbloom Barry⁷,Dussen Laura¹,Tylki-Szymańska Anna⁸,Weinreb Neal J.⁹,Zimran Ari¹⁰,Cappellini Maria Domenica¹¹

Affiliation:

1. Department of Internal Medicine; Division of Endocrinology and Metabolism; Academic Medical Centre; University of Amsterdam; Amsterdam; The Netherlands

2. Reference Centre for Lysosomal Diseases; Beaujon Hospital; Assistance Publique-Hôpitaux de Paris; Clichy; France

3. Genzyme, a Sanofi Company; Cambridge; MA; USA

4. Department of Internal Medicine; St Franziskus Hospital; Teaching Hospital; University of Cologne; Cologne; Germany

5. Department of Medicine; Addenbrooke's Hospital; Cambridge; UK

6. Genetic Services of Western Australia; School of Paediatrics and Child Health; University of Western Australia; Perth; WA; Australia

7. Tower Hematology Oncology Medical Group; Beverly Hills; CA; USA

8. Department of Metabolic Diseases; The Children's Memorial Health Institute; Warsaw; Poland

9. University Research Foundation for Lysosomal Storage Disorders; Coral Springs; FL; USA

10. Gaucher Clinic; Shaare Zedek Medical Centre; Hebrew University; Jerusalem; Israel

11. Department of Internal Medicine; “Ca Granda” Policlinico Foundation IRCCS; University of Milan; Milan; Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2012.09175.x/fullpdf

Reference44 articles.

1. Proteinase-activated receptor (PAR1) polymorphic variant correlates with thrombocytopenia in Gaucher disease;Altarescu;Blood Cells Molecules and Diseases,2010

2. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1;Andersson;Pediatrics,2008

3. Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia;Aster;Journal of Clinical Investigations,1966

4. A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation;Aviezer;PLoS ONE,2009

5. Continuing developments with the automated platelet count;Briggs;International Journal of Laboratory Hematology,2007

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies;Frontiers in Pharmacology;2024-02-13

2. Morbus Gaucher;Therapie-Handbuch - Gastroenterologie und Hepatologie;2024

3. Use of Ambroxol as Therapy for Gaucher Disease;JAMA Network Open;2023-06-21

4. Hemostatic Abnormalities in Gaucher Disease: Mechanisms and Clinical Implications;Journal of Clinical Medicine;2022-11-24

5. Lipidoses: The Sphingolipidoses, Lysosomal Acid Lipase Deficiency, and Niemann-Pick Type C;Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases;2022